Dosage forms

RYAH Medtech Inc. Ships Devices for Use in Pilot Study with CLINN Medical Center

Retrieved on: 
Tuesday, May 25, 2021
Dosage forms, Medtech, Asthma, Respiratory therapy, Zimmer Biomet Robotics, Inhaler, Health sciences, Health care, Health

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc.s (CSE:RYAH) (RYAH or the Company) wholly owned subsidiary, RYAH Medtech Inc. (RYAH Medtech), announces it has completed initial shipment of its proprietary Smart Dose-Measuring inhalers for use in a pilot study conducted by CLINN medical center in Milan, Italy.

Key Points: 
  • NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc.s (CSE:RYAH) (RYAH or the Company) wholly owned subsidiary, RYAH Medtech Inc. (RYAH Medtech), announces it has completed initial shipment of its proprietary Smart Dose-Measuring inhalers for use in a pilot study conducted by CLINN medical center in Milan, Italy.
  • We are delighted to bring RYAH Medtech's Smart-Inhaler to the CLINN network and support CLINN in integrating their data collection software.
  • RYAH Medtech Inc. (RYAH) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry.
  • With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Respiratory therapy, Health sciences, Health, Chronic lower respiratory diseases, Dosage forms, Chronic obstructive pulmonary disease, Nebulizer, Forward-looking statement

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration

Retrieved on: 
Monday, May 24, 2021
Prostaglandins, Secondary alcohols, Treprostinil, Dosage forms, Subcutaneous injection, Injection, Health, Chemistry, Physical sciences

Both options for intravenous and SC administration of Sandoz generic Treprostinil Injection are now available at the same specialty pharmacy that dispenses the brand name medicine.

Key Points: 
  • Both options for intravenous and SC administration of Sandoz generic Treprostinil Injection are now available at the same specialty pharmacy that dispenses the brand name medicine.
  • Patients who need and depend on subcutaneously administered treprostinil will now, for the first time, have access to a lower cost generic treprostinil.
  • The cartridges required to operate the CADD-MS 3 pump were not available to patients using generic Treprostinil Injection due to restrictions imposed by other companies.
  • CADD-MS 3 is a registered trademark of Smiths Medical ASD, Inc.
    Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration.

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Medicine, Health sciences, Nose, Dosage forms, Routes of administration, Sensory organs, Nasal administration, Nasal cavity, Drug delivery, Nasal

b'IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device.

Key Points: 
  • b'IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device.
  • The device will be used to deliver the Company\xe2\x80\x99s drug candidate, PRV-002 for concussion treatment and is designed to enhance bio-distribution to the brain.
  • The nasal device will be used in phase 1 clinical trials being scheduled in Australia this summer.
  • \xe2\x80\x9cThis innovation will provide more uniform drug distribution to the nasal cavity while enhancing availability to the brain.

Global Transdermal Drug Delivery Research Report 2021: Markets, Technologies, and Competitive Landscape 2020-2030 Featuring 100 Companies & 105 Collaborations - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Health, Pharmaceutical, Health sciences, Routes of administration, Pharmacology, Medicine, Dosage forms, Transdermal patch, Transdermal, Drug delivery

b'The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2020 to 2030.

Key Points: 
  • b'The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2020 to 2030.
  • This market is analyzed according to geographical regions as well.\nThis report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral, intravascular, subcutaneous, and transmucosal routes.
  • Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers.\nThe most commonly used transdermal system is the skin patch using various types of technologies.
  • Nanoparticles as well as the use of physical agents to facilitate transcutaneous drug delivery is described.

Colorcon Expands Pharmaceutical Development Capabilities with a New Containment Suite for Handling High Potency APIs at its Global Technical Center in Harleysville, PA, USA

Retrieved on: 
Wednesday, May 19, 2021
Health sciences, Pharmacology, Dosage forms, Pharmaceutical sciences, Pharmaceutical industry, Chemical engineering, Pharmacokinetics, Tablet, Capsule, Active ingredient

The Containment Suite provides the capability to develop prototype tablet or capsule dosage forms for clients when active pharmaceutical ingredient (API) quantity is limited and/or the API potency requires a higher level of protection.

Key Points: 
  • The Containment Suite provides the capability to develop prototype tablet or capsule dosage forms for clients when active pharmaceutical ingredient (API) quantity is limited and/or the API potency requires a higher level of protection.
  • The lab utilizes mobile isolation modules to offer maximum process flexibility.\nKurt Fegely, Managing Director, Colorcon Americas, states "investing in this facility demonstrates Colorcon\'s continued commitment to supporting pharmaceutical development in North America, reducing our customer\'s time to market and reflects our dedication to providing unparalleled products and services.
  • We can now offer a complete cycle starting from the customer\'s API, all the way to a finished coated dosage form within our facilities and provide prototypes ready for customer evaluation.
  • Our investment in the best equipment enables us to produce tablets and capsules with milligrams of active product in the safest of conditions.

Milestone Scientific Schedules First Quarter 2021 Business Update Conference Call

Retrieved on: 
Wednesday, May 12, 2021
Medical specialties, Clinical medicine, Medicine, Dosage forms, Childbirth, Epidural administration, Regional anesthesia, Anesthesia, Joint injection, Botulinum toxin

b"ROSELAND, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, May 17, 2021 to discuss the Company\xe2\x80\x99s financial results for the first quarter ended March 31, 2021, as well as the Company\xe2\x80\x99s corporate progress and other developments.\nThe conference call will be available via telephone by dialing toll free 1-877-407-0778 for U.S. callers or 201-689-8565 for international callers.

Key Points: 
  • b"ROSELAND, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, May 17, 2021 to discuss the Company\xe2\x80\x99s financial results for the first quarter ended March 31, 2021, as well as the Company\xe2\x80\x99s corporate progress and other developments.\nThe conference call will be available via telephone by dialing toll free 1-877-407-0778 for U.S. callers or 201-689-8565 for international callers.
  • Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless.
  • Milestone\xe2\x80\x99s proprietary DPS Dynamic Pressure Sensing technology\xc2\xae is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.
  • For more information please visit our website: www.milestonescientific.com .\n"

Global Nebulizers (Pneumatic, Ultrasonic, Mesh) Market Report 2021: COVID-19 Impacts, Implications and Growth to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Medical devices, Health, Medicine, Health sciences, Health, Respiratory therapy, Medical equipment, Dosage forms, Aerosols, Nebulizer, Asthma, COVID-19, Respiratory disease, Respiratory therapist

b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.

Key Points: 
  • b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.
  • The market is expected to reach $1.55 billion in 2025 at a CAGR of 10.5%.\nThe nebulizer devices market consists of sales of nebulizers used in respiratory care for patients with respiratory diseases including asthma, cystic fibrosis and COPD.
  • There has been an increased use of albuterol inhalers in hospitals for Covid-19 and suspected Covid-19 patients to help with respiratory issues.
  • Rise in geriatric population is anticipated to propel the nebulizer market growth.\n'

Spyder Cannabis Announces Management and Board Changes

Retrieved on: 
Monday, May 10, 2021
Tobacco, Psychoactive drugs, Smoking, Electronic cigarettes, Cannabis smoking, Dosage forms, Smoking cessation, Euphoriants, Vaporizer, Electronic cigarette, Cannabis, Gopal Bhatnagar

This acquisition has given Spyder access to an iconic brand name, local customer base and a talented management team."

Key Points: 
  • This acquisition has given Spyder access to an iconic brand name, local customer base and a talented management team."
  • Additionally, we look forward to immediately converting some of 180 Smoke\'s existing vape retail locations to licensed cannabis dispensaries.
  • He specializes in navigating early-stage financing structures, M&A and ongoing management of public companies having significant experience in managing corporate finance, audit and legal teams.
  • 180 Smoke and Spyder Vape retail stores sell vape and nicotine-related products, herbal vaporizers and accessories, and other smoking cessation products.

Worldwide Medical Oxygen Industry to 2026 - Key Drivers and Challenges

Retrieved on: 
Thursday, May 6, 2021
Oxygen, Chemistry, Medicine, Physical sciences, Industrial gases, Respiratory therapy, Medical equipment, Dosage forms, Oxygen concentrator, Oxygen therapy, Oxygen firebreak

The Global Medical Oxygen Market is driven by the growing prevalence of respiratory diseases among the population.

Key Points: 
  • The Global Medical Oxygen Market is driven by the growing prevalence of respiratory diseases among the population.
  • This is acting as a pivotal factor for the growth of the medical oxygen market in recent times.\nThe Global Medical Oxygen Market is segmented based on form, purity, delivery mode, modality, technology, application, end-user, company, and region.
  • Based on form, the market can be categorized into compressed, liquid oxygen, oxygen concentrators, others.
  • These companies are significantly increasing their training efforts to meet the rising demand for oxygen concentrators in order to expand their market share.\nYears considered for this report:\n'